Tevogen Bio Holdings Inc. (TVGN)
Automate Your Wheel Strategy on TVGN
With Tiblio's Option Bot, you can configure your own wheel strategy including TVGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TVGN
- Rev/Share 0.0025
- Book/Share -0.0478
- PB -20.4893
- Debt/Equity -0.6246
- CurrentRatio 0.353
- ROIC 12.1994
- MktCap 181979571.0
- FreeCF/Share -0.0814
- PFCF -13.8462
- PE -4.4735
- Debt/Assets 1.1838
- DivYield 0
- ROE 5.0122
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TVGN | D. Boral Capital | -- | Buy | -- | $10 | March 4, 2025 |
News
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), reiterates investor confidence and estimated asset value over $10 billion.
Read More
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.
Read More
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.
Read More
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
Published: August 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC).
Read More
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model.
Read More
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.
Read More
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it expects to receive $1 million in grant funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development program.
Read More
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company's significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission.
Read More
Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today welcomes the White House's release of “Winning the Race: America's AI Action Plan”, issued July 23, 2025. The Company applauds the federal government's emphasis on establishing domain-specific standards, regulatory sandboxes (aka AI Centers of Excellence), and stakeholder convenings led by The National Institute of Standards and Technology to build trust, governance, and productivity in healthcare AI.
Read More
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models."
Read More
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, should support the Company's cell therapy manufacturing operations.
Read More
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
Published: July 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 16, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that following the completion and deployment of the alpha version of PredicTcell™, a proprietary AI-driven target discovery platform, the Company now plans to expand Tevogen.AI to include patient data against identified targets.
Read More
Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, in collaboration with Microsoft (Nasdaq: MSFT) and Databricks, has successfully built the alpha version of its foundational PredicTcell™ model.
Read More
Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
Published: July 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the completion and official opening of its fully functional, newly expanded corporate headquarters in Warren, New Jersey. The build-out and first-year operating costs were personally gifted by Founder and Chief Executive Officer Ryan Saadi, M.D., M.P.H., resulting in no expense to the Company or its shareholders.
Read More
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
Published: June 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that founder and Chief Executive Officer, Ryan Saadi, M.D., M.P.H., has personally contributed $500,000 towards the build-out and first-year operating costs of Tevogen's new corporate headquarters in Warren, New Jersey.
Read More
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
Published: June 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
R&D and cross-functional operations will be centralized in a single location to enhance collaboration and operational efficiency. Tevogen.AI, strengthened by its partnership with Microsoft, continues to expand.
Read More
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™.
Read More
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced a planned expansion of TVGN 489's target population to include patients 65 and older. As previously reported in October 2024, the top-line revenue forecast for the specialty care pipeline was projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between $18 billion and $22 billion. This anticipated expansion aims to broaden the market potential of Tevogen's specialty pharmaceuticals. An updated forecast and the risk adjusted net present value (rNPV) will be provided to reflect the …
Read More
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it will provide several updates to stockholders in advance of the Company's upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company's innovative business model and strategic growth initiatives, which management believes position the Company strongly for future value realization.
Read More
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN). As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio's innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare.
Read More
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest
Published: May 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that, following the Company's recent press release highlighting the Direct Registration System (DRS) as a secure method of share ownership, it has received a number of inquiries from shareholders seeking additional information on how to transfer their shares to a DRS account.
Read More
CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that CD8 Technology Services LLC (“CD8”) has signed a letter of intent for a facility designed to support Tevogen Bio's cell therapy manufacturing facility.
Read More
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today informed shareholders about several differences between holding shares in Direct Registration System (“DRS”) accounts and holding them in brokerage accounts.
Read More
Tevogen Bio Announces 2025 Annual Meeting
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN) today announced that the Company will hold its 2025 annual meeting of stockholders (the “Annual Meeting”) via live webcast at 11 a.m. Eastern Time on June 23, 2025. Stockholders of record as of April 30, 2025, will be asked to vote on the re-election of two incumbent director nominees, and the ratification of the Company's independent registered public accounting firm.
Read More
Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility
Published: April 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced it has entered into an agreement with CD 8 Technology Services LLC (“CD8”) for the development and/or acquisition of a turn-key facility that is intended to support both in-house pre-clinical research and GMP cell therapy production capabilities.
Read More
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction
Published: April 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced the commission of Databricks, Inc., a leader in data, analytics and artificial intelligence (AI), with an aim to accelerate the development of PredicTcell, the Company's proprietary AI-driven target prediction model for precision immunotherapy.
Read More
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
Published: April 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald.
Read More
Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States
Published: April 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announces its newest effort: Tevogen Generics. This effort is in response to the growing national focus on pharmaceutical affordability and coincides with the recent tariff-related statements from President Donald Trump.
Read More
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access.
Read More
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, today announced the filing of a new patent with the U.S. Patent and Trademark Office (USPTO) for its under-development T cell vaccine. Unlike many vaccines that primarily induce a B cell response, Tevogen Bio's design aims to leverage the Company's proprietary Tevogen.AI-powered PredicTcell technology to identify peptides which stimulate a T cell response.
Read More
About Tevogen Bio Holdings Inc. (TVGN)
- IPO Date 2022-01-05
- Website https://tevogen.com
- Industry Biotechnology
- CEO Ryan H. Saadi M.P.H,
- Employees 18